[96a5a0]: / output / allTrials / identified / NCT05683691_identified.json

Download this file

974 lines (974 with data), 43.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
{
"info": {
"nct_id": "NCT05683691",
"official_title": "Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR",
"inclusion_criteria": "1. ≥50 years of age; with life expectancy of ≥10 years\n2. 20-80 cc prostate size determined by MRI Central Imaging\n3. ≤15 ng/ml PSA\n4. Cancer stage less than or equal to T2c\n5. Within 12 months prior to signing consent have had a multiparametric MRI. Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal). This must include a standard sector biopsy obtaining a minimum of 10 cores.\n\n * <15mm diameter of qualifying lesion as measure by greatest diameter\n6. Subject is willing and able to adhere to specific protocol visits and required testing throughout study\n7. Is geographically stable and near the site or able and willing to travel back to site for follow-up visits involving diagnostic tests or treatment\n8. Able and willing to provide written consent to participate in the study.\n9. Subject is willing and able to be treated within 180 days after signing consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 50 Years",
"exclusion_criteria": "1. Patients with >GGG3 cores anywhere in the prostate\n2. MRI evidence of extracapsular extension of cancer (MRI read as \"definite\", \"frank\" or \"gross\" ECE)\n3. All MRI Central Imaging confirmed PI-RADS 5 lesions\n4. All MRI Central Imaging confirmed additional PI-RADS 4 lesions.\n5. Contraindications to MRI\n6. Subjects with an installed pacemaker or other potentially electrically conductive implants implanted within 200mm (8 inches) of the procedure area. Implants that are within 200mm (8 inches) and can be turned off for the duration of the study procedure are acceptable.\n7. Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the prostate cancer or bladder neck.\n8. Treated within the past 5 years for genital cancer\n9. Presence of any urethral or prostatic condition that precludes water vapor ablation per Instructions for Use\n10. Currently taking medications that have hormonal effects on the prostate or PSA, such as: 5 alpha reductase inhibitors (if on for <6 months, 6-month washout), Androgen blockers, Luteinizing hormone-releasing hormone (LHRH) agonists or antagonists (12-month washout), or Testosterone supplementation (3-month washout)\n11. Active urinary tract infection. Subjects with an active infection who can be treated and re-tested with a negative result within the screening window are acceptable.\n12. Active or clinically chronic prostatitis or granulomatous prostatitis\n13. Treated within the past 5 years for a lower and/or upper urinary tract malignancy.\n14. Any previous treatment for prostate cancer.\n15. Any rectal pathology, anomaly or previous treatment that could change properties of rectal wall or insertion and use of TRUS\n16. Unable to stop taking antiplatelet medications or other blood thinning agents\n17. Known allergy to nickel\n18. Allergic to medication required by the study such as MRI contrast or anesthesia\n19. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study\n20. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life questionnaires\n21. Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing\n22. Subject is considered vulnerable such as incarcerated or cognitively impaired.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. ≥50 years of age; with life expectancy of ≥10 years",
"criterions": [
{
"exact_snippets": "≥50 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "years"
}
}
]
},
{
"exact_snippets": "life expectancy of ≥10 years",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "years"
}
}
]
}
]
},
{
"line": "2. 20-80 cc prostate size determined by MRI Central Imaging",
"criterions": [
{
"exact_snippets": "20-80 cc prostate size determined by MRI Central Imaging",
"criterion": "prostate size",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 20,
"unit": "cc"
},
{
"operator": "<=",
"value": 80,
"unit": "cc"
}
]
}
}
]
}
]
},
{
"line": "3. ≤15 ng/ml PSA",
"criterions": [
{
"exact_snippets": "≤15 ng/ml PSA",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 15,
"unit": "ng/ml"
}
}
]
}
]
},
{
"line": "4. Cancer stage less than or equal to T2c",
"criterions": [
{
"exact_snippets": "Cancer stage less than or equal to T2c",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "T"
}
}
]
}
]
},
{
"line": "5. Within 12 months prior to signing consent have had a multiparametric MRI. Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate (transrectal or transperineal). This must include a standard sector biopsy obtaining a minimum of 10 cores.",
"criterions": [
{
"exact_snippets": "Within 12 months prior to signing consent have had a multiparametric MRI.",
"criterion": "multiparametric MRI",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 12,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "Within 6 months prior to signing consent, have undergone a multiparametric MRI software guided fusion biopsy of the prostate",
"criterion": "multiparametric MRI software guided fusion biopsy of the prostate",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 6,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "This must include a standard sector biopsy obtaining a minimum of 10 cores.",
"criterion": "standard sector biopsy",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "cores"
}
}
]
}
]
},
{
"line": "* <15mm diameter of qualifying lesion as measure by greatest diameter",
"criterions": [
{
"exact_snippets": "<15mm diameter of qualifying lesion",
"criterion": "qualifying lesion",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": "<",
"value": 15,
"unit": "mm"
}
}
]
}
]
},
{
"line": "6. Subject is willing and able to adhere to specific protocol visits and required testing throughout study",
"criterions": [
{
"exact_snippets": "Subject is willing and able to adhere to specific protocol visits",
"criterion": "adherence to protocol visits",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "Subject is willing and able to adhere to ... required testing throughout study",
"criterion": "adherence to required testing",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "7. Is geographically stable and near the site or able and willing to travel back to site for follow-up visits involving diagnostic tests or treatment",
"criterions": [
{
"exact_snippets": "Is geographically stable",
"criterion": "geographical stability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "near the site",
"criterion": "proximity to site",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "able and willing to travel back to site",
"criterion": "willingness and ability to travel",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "8. Able and willing to provide written consent to participate in the study.",
"criterions": [
{
"exact_snippets": "Able and willing to provide written consent",
"criterion": "consent to participate",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
},
{
"requirement_type": "willingness",
"expected_value": true
},
{
"requirement_type": "form",
"expected_value": "written"
}
]
}
]
},
{
"line": "9. Subject is willing and able to be treated within 180 days after signing consent.",
"criterions": [
{
"exact_snippets": "Subject is willing and able to be treated",
"criterion": "willingness and ability to be treated",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "within 180 days after signing consent",
"criterion": "treatment timeline",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": {
"operator": "<=",
"value": 180,
"unit": "days"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 50 Years",
"criterions": [
{
"exact_snippets": "minimum age of 50 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients with >GGG3 cores anywhere in the prostate",
"criterions": [
{
"exact_snippets": "Patients with >GGG3 cores anywhere in the prostate",
"criterion": "GGG cores in the prostate",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "GGG cores"
}
}
]
}
]
},
{
"line": "2. MRI evidence of extracapsular extension of cancer (MRI read as \"definite\", \"frank\" or \"gross\" ECE)",
"criterions": [
{
"exact_snippets": "MRI evidence of extracapsular extension of cancer",
"criterion": "extracapsular extension of cancer",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": "MRI"
}
]
},
{
"exact_snippets": "MRI read as \"definite\", \"frank\" or \"gross\" ECE",
"criterion": "MRI read",
"requirements": [
{
"requirement_type": "interpretation",
"expected_value": [
"definite",
"frank",
"gross"
]
}
]
}
]
},
{
"line": "3. All MRI Central Imaging confirmed PI-RADS 5 lesions",
"criterions": [
{
"exact_snippets": "MRI Central Imaging confirmed PI-RADS 5 lesions",
"criterion": "PI-RADS lesions",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "MRI Central Imaging"
},
{
"requirement_type": "PI-RADS score",
"expected_value": {
"operator": "=",
"value": 5,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "4. All MRI Central Imaging confirmed additional PI-RADS 4 lesions.",
"criterions": [
{
"exact_snippets": "MRI Central Imaging confirmed additional PI-RADS 4 lesions",
"criterion": "PI-RADS lesions",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
},
{
"requirement_type": "PI-RADS score",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "5. Contraindications to MRI",
"criterions": [
{
"exact_snippets": "Contraindications to MRI",
"criterion": "MRI contraindications",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "6. Subjects with an installed pacemaker or other potentially electrically conductive implants implanted within 200mm (8 inches) of the procedure area. Implants that are within 200mm (8 inches) and can be turned off for the duration of the study procedure are acceptable.",
"criterions": [
{
"exact_snippets": "installed pacemaker",
"criterion": "pacemaker",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "other potentially electrically conductive implants",
"criterion": "electrically conductive implants",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "implanted within 200mm (8 inches) of the procedure area",
"criterion": "implant location",
"requirements": [
{
"requirement_type": "distance from procedure area",
"expected_value": {
"operator": "<=",
"value": 200,
"unit": "mm"
}
}
]
},
{
"exact_snippets": "Implants that are within 200mm (8 inches) and can be turned off for the duration of the study procedure are acceptable",
"criterion": "implant functionality",
"requirements": [
{
"requirement_type": "ability to be turned off",
"expected_value": true
}
]
}
]
},
{
"line": "7. Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the prostate cancer or bladder neck.",
"criterions": [
{
"exact_snippets": "Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the prostate cancer",
"criterion": "prior prostate cancer treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Any prior surgery, intervention, or minimally invasive therapy, (MIST) for the ... bladder neck",
"criterion": "prior bladder neck treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "8. Treated within the past 5 years for genital cancer",
"criterions": [
{
"exact_snippets": "Treated within the past 5 years for genital cancer",
"criterion": "treatment for genital cancer",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
}
]
},
{
"line": "9. Presence of any urethral or prostatic condition that precludes water vapor ablation per Instructions for Use",
"criterions": [
{
"exact_snippets": "Presence of any urethral or prostatic condition that precludes water vapor ablation",
"criterion": "urethral or prostatic condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "impact on treatment",
"expected_value": "precludes water vapor ablation"
}
]
}
]
},
{
"line": "10. Currently taking medications that have hormonal effects on the prostate or PSA, such as: 5 alpha reductase inhibitors (if on for <6 months, 6-month washout), Androgen blockers, Luteinizing hormone-releasing hormone (LHRH) agonists or antagonists (12-month washout), or Testosterone supplementation (3-month washout)",
"criterions": [
{
"exact_snippets": "Currently taking medications that have hormonal effects on the prostate or PSA",
"criterion": "medications with hormonal effects on prostate or PSA",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "5 alpha reductase inhibitors (if on for <6 months, 6-month washout)",
"criterion": "5 alpha reductase inhibitors",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
},
{
"requirement_type": "washout period",
"expected_value": {
"operator": "=",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Androgen blockers",
"criterion": "Androgen blockers",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Luteinizing hormone-releasing hormone (LHRH) agonists or antagonists (12-month washout)",
"criterion": "Luteinizing hormone-releasing hormone (LHRH) agonists or antagonists",
"requirements": [
{
"requirement_type": "washout period",
"expected_value": {
"operator": "=",
"value": 12,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Testosterone supplementation (3-month washout)",
"criterion": "Testosterone supplementation",
"requirements": [
{
"requirement_type": "washout period",
"expected_value": {
"operator": "=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "11. Active urinary tract infection. Subjects with an active infection who can be treated and re-tested with a negative result within the screening window are acceptable.",
"criterions": [
{
"exact_snippets": "Active urinary tract infection",
"criterion": "urinary tract infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Subjects with an active infection who can be treated and re-tested with a negative result within the screening window are acceptable",
"criterion": "urinary tract infection",
"requirements": [
{
"requirement_type": "treatability",
"expected_value": true
},
{
"requirement_type": "re-test result",
"expected_value": "negative"
}
]
}
]
},
{
"line": "12. Active or clinically chronic prostatitis or granulomatous prostatitis",
"criterions": [
{
"exact_snippets": "Active or clinically chronic prostatitis",
"criterion": "prostatitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "type",
"expected_value": [
"active",
"clinically chronic"
]
}
]
},
{
"exact_snippets": "granulomatous prostatitis",
"criterion": "granulomatous prostatitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "13. Treated within the past 5 years for a lower and/or upper urinary tract malignancy.",
"criterions": [
{
"exact_snippets": "Treated within the past 5 years",
"criterion": "treatment for urinary tract malignancy",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
},
{
"exact_snippets": "lower and/or upper urinary tract malignancy",
"criterion": "urinary tract malignancy",
"requirements": [
{
"requirement_type": "location",
"expected_value": [
"lower",
"upper"
]
}
]
}
]
},
{
"line": "14. Any previous treatment for prostate cancer.",
"criterions": [
{
"exact_snippets": "Any previous treatment for prostate cancer.",
"criterion": "previous treatment for prostate cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "16. Unable to stop taking antiplatelet medications or other blood thinning agents",
"criterions": [
{
"exact_snippets": "Unable to stop taking antiplatelet medications",
"criterion": "antiplatelet medications",
"requirements": [
{
"requirement_type": "ability to stop",
"expected_value": false
}
]
},
{
"exact_snippets": "Unable to stop taking ... other blood thinning agents",
"criterion": "blood thinning agents",
"requirements": [
{
"requirement_type": "ability to stop",
"expected_value": false
}
]
}
]
},
{
"line": "17. Known allergy to nickel",
"criterions": [
{
"exact_snippets": "Known allergy to nickel",
"criterion": "allergy to nickel",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "18. Allergic to medication required by the study such as MRI contrast or anesthesia",
"criterions": [
{
"exact_snippets": "Allergic to medication required by the study such as MRI contrast",
"criterion": "allergy to MRI contrast",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Allergic to medication required by the study such as ... anesthesia",
"criterion": "allergy to anesthesia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "19. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study",
"criterions": [
{
"exact_snippets": "significant medical history",
"criterion": "medical history",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
}
]
},
{
"exact_snippets": "pose an unreasonable risk",
"criterion": "risk",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "unreasonable"
}
]
},
{
"exact_snippets": "make the subject unsuitable for the study",
"criterion": "suitability for the study",
"requirements": [
{
"requirement_type": "suitability",
"expected_value": false
}
]
}
]
},
{
"line": "20. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator regarding the study or affects the ability to complete the study quality of life questionnaires",
"criterions": [
{
"exact_snippets": "Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study Investigator",
"criterion": "cognitive or psychiatric condition",
"requirements": [
{
"requirement_type": "interference with communication",
"expected_value": true
}
]
},
{
"exact_snippets": "Any cognitive or psychiatric condition that ... affects the ability to complete the study quality of life questionnaires",
"criterion": "cognitive or psychiatric condition",
"requirements": [
{
"requirement_type": "affects ability to complete questionnaires",
"expected_value": true
}
]
}
]
},
{
"line": "21. Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing",
"criterions": [
{
"exact_snippets": "Subject currently participating in other premarket investigational studies",
"criterion": "participation in other premarket investigational studies",
"requirements": [
{
"requirement_type": "participation",
"expected_value": false
}
]
}
]
},
{
"line": "22. Subject is considered vulnerable such as incarcerated or cognitively impaired.",
"criterions": [
{
"exact_snippets": "Subject is considered vulnerable such as incarcerated",
"criterion": "vulnerability",
"requirements": [
{
"requirement_type": "status",
"expected_value": "incarcerated"
}
]
},
{
"exact_snippets": "Subject is considered vulnerable such as ... cognitively impaired",
"criterion": "vulnerability",
"requirements": [
{
"requirement_type": "status",
"expected_value": "cognitively impaired"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "15. Any rectal pathology, anomaly or previous treatment that could change properties of rectal wall or insertion and use of TRUS",
"criterions": [
{
"exact_snippets": "Any rectal pathology",
"criterion": "rectal pathology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "any ... anomaly",
"criterion": "rectal anomaly",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "previous treatment that could change properties of rectal wall",
"criterion": "previous treatment affecting rectal wall",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "previous treatment that could change properties of ... insertion and use of TRUS",
"criterion": "previous treatment affecting TRUS use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"failed_miscellaneous": []
}